Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Giving the drugs in different ways may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of gemcitabine given directly into the
bladder in treating patients who have recurrent or refractory bladder cancer.